Thalidomide therapy for cicatricial pemphigoid - 11/05/12
Doi : 10.1067/mjd.2002.109255
Daihung Jay Duong, MDa, Richard T. Moxley, MDa, Robert M. Kellman, MDb, Stephanie H. Pincus, MDc, Anthony A. Gaspari, MDc
Syracuse, Buffalo, and Rochester, New York
From the Departments of Neurology and Otolaryngology,a State University of New York at Syracuse, Department of Dermatology, State University of New York at Buffalo,b and Departments of Dermatology and Microbiology/Immunology and the Cancer Center, University of Rochester School of Medicine and Dentistry.c
Abstract |
Cicatricial pemphigoid is a chronic, presumed autoimmune, blistering disease of the mucous membranes and occasionally of the skin. The characteristic feature is scarring at the sites of healing. We report the use of thalidomide as a therapeutic agent to control previously resistant disease. (J Am Acad Dermatol 2002;47:S193-5).
Le texte complet de cet article est disponible en PDF.Plan
 | This supplement is made possible through an unrestricted educational grant from Stiefel Laboratories to the American Academy of Dermatology. |
| Supported by NIH grant 1R01AH/OH4108-03. |
 | Reprint requests: Anthony A. Gaspari, MD, Departments of Dermatology, Microbiology/Immunology and Cancer Center, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642. E-mail: anthony_gaspari@urmc.rochester.edu. |
© 2002
American Academy of Dermatology, Inc. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 47 - N° 2S
P. S193-S195 - août 2002 Retour au numéro
Article précédent
- Coexistence of pseudoxanthoma elasticum–like papillary dermal elastolysis and linear focal dermal elastosis
- Atsushi Akagi, Shingo Tajima, Akira Kawada, Akira Ishibashi
- Neurocutaneous melanosis in association with encephalocraniocutaneous lipomatosis
- Iftikhar Ahmed, Whitney D. Tope, Terri L. Young, Danielle M. Miller, Kenneth E. Bloom
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?